Bacterial conjunctivitis
========================

**Definition:** Bacterial conjunctivitis is inflammation of the conjunctiva as a result of bacterial infection.

**Etiology:** Most commonly *Staphylococcus* species in adults, and *Streptococcus pneumonia* and the Gram-negative organisms *Haemophilus influenzae* and *Moraxella catarrhalis* in children. Contact lens wearers are at particular risk for Gram-negative infections. such as *Pseudomonas aeruginosa. Neisseria gonorrhoeae* is primarily a neonatal etiology.

**Incidence:** One recent study estimates an annual incidence rate of 135 per 10,000 in the US.1

**Economics:** The same study found the estimated total direct and indirect cost of treating bacterial conjunctivitis in the US to be \$589 million annually. Accounting for a 20% variation in annual incidence rate and treatment cost resulted in an estimated cost range of \$377 to \$857 million per year.

**Level of evidence used in this summary:** Systematic reviews, meta-analyses, and randomized controlled trials from 1990 to 2010.

**Search sources:** Ovid MEDLINE, PubMed, Cochrane Library, NHS evidence, Clinical Evidence.

**Outcomes:** From the patient perspective, the main outcomes are:

1.  Speed of symptomatic resolution

2.  Convenience of treatment

3.  Avoidance of complications.

**Consumer summary:** Bacterial conjunctivitis is inflammation of the conjunctiva caused by direct contact with infected secretions. The most common organisms are *Staphylococcus* species, *S. pneumonia*, *H. influenzae*, and *M. catarrhalis*. It presents with conjunctival injection, mucopurulent discharge, and crusty eyelids. The diagnosis is usually clinical. The condition is often self-limiting, but there is good evidence that antibiotics improve remission rates. Most of the current evidence suggests that the choice of topical antibiotics and the treatment regimen do not significantly affect the rate of recovery from infection. Failure to recognize and treat bacterial conjunctivitis may lead to complications, such as keratitis or anterior uveitis.

The evidence
============

Do any interventions make a difference to the resolution of bacterial conjunctivitis?
-------------------------------------------------------------------------------------

  ------------------------------- ----
  Systematic reviews:             2
  Meta-analyses:                  1
  Randomized controlled trials:   10
  ------------------------------- ----

The Cochrane systematic review,[@b2-opth-4-1451] which includes a meta-analysis, concluded that "acute bacterial conjunctivitis is frequently a self-limiting condition, but the use of antibiotics is associated with significantly improved rates of clinical and microbiological remission". The systematic review by *Clinical Evidence*[@b3-opth-4-1451] concludes that topical antibiotics are " beneficial" in people with culture-positive nongonococcal bacterial conjunctivitis and "likely to be beneficial" when used empirically in people with suspected bacterial conjunctivitis within 1--2 days if symptoms do not resolve on their own. Oral antibiotics, ocular decongestants, warm compresses, and saline were found to be of "unknown effectiveness".

Most randomized controlled trials (see [Table 1](#t1-opth-4-1451){ref-type="table"}) showed that topical antibiotics accelerate bacterial eradication and help resolve the signs and symptoms of bacterial conjunctivitis. However, in two trials,[@b4-opth-4-1451],[@b5-opth-4-1451] clinical recovery at seven days after presentation was found to be unaffected by the use of antibiotics, even though one of the two trials[@b4-opth-4-1451] still found an improvement in microbial cure rate with antibiotics.

Which antibiotics are best for accelerating resolution of bacterial conjunctivitis?
-----------------------------------------------------------------------------------

  ------------------------------- ----
  Systematic reviews:             1
  Meta-analyses:                  0
  Randomized controlled trials:   26
  ------------------------------- ----

[Table 2](#t2-opth-4-1451){ref-type="table"} lists the antibiotics studied, along with their microbial coverage, mechanism of action, and availability. The systematic review[@b3-opth-4-1451] concluded that "there is no clear best choice for topical antibiotics -- local microbiological resistance patterns, cost, dosing regimens, and other patient factors (such as allergies and compliance) are important considerations in addition to efficacy". Results from randomized controlled trials ([Table 3](#t3-opth-4-1451){ref-type="table"}) are varied, but many found similar clinical and microbiologic efficacy among the topical antibiotics used. Some studies found faster bacterial eradication and/or clinical recovery with fluoroquinolones, azithromycin, or netilimicin compared with the more traditional antibiotics, such as tobramycin or polymyxin B/trimethoprim or gentamicin. Some studies found differences in patient compliance with different antibiotics. Microbiologic resistance patterns can also vary and would affect efficacy rates.

Which treatment regimen works best for bacterial conjunctivitis?
----------------------------------------------------------------

  ------------------------------- ---
  Systematic reviews:             0
  Meta-analyses:                  0
  Randomized controlled trials:   4
  ------------------------------- ---

A few randomized controlled trials ([Table 4](#t4-opth-4-1451){ref-type="table"}) have focused on the effect of the treatment regimen, such as dosing, frequency, length of treatment, and route of administration, on efficacy rates. None have found a significant change in cure rate in association with the treatment regimen used.

Conclusions
===========

Bacterial conjunctivitis often resolves on its own, but the current evidence suggests that topical antibiotics help accelerate recovery from this self-limiting disease. Topical antibiotics used for treatment of bacterial conjunctivitis have similar efficacy rates. The treatment regimen does not affect recovery from bacterial conjunctivitis. Patients may prefer a simpler regimen.

The practice
============

Potential pitfalls
------------------

-   Contact lens wearers are predisposed to Gram-negative infections, carrying a higher risk of complications, such as bacterial keratitis. Pseudomonas and Acanthamoeba infections in contact lens wearers can lead to serious, sight-threatening complications if not recognized and treated appropriately. The contact lens storage case may be the nidus of the infection.

-   If there is an associated keratitis or anterior uveitis, referral to a specialist may be recommended

-   Beware of combination topical antibiotic agents that contain steroids. These should be used with extreme caution and monitored by a specialist.

Management
----------

Bacterial conjunctivitis can be managed by nonspecialists.

Assessment
----------

-   Redness, foreign body sensation and purulent/ mucopurulent discharge are common complaints; there may be itching, chemosis, or conjunctival papillae

-   Ask about contact lens wear

-   Assess for corneal involvement and intraocular involvement

-   Conjunctival swabs can be done for Gram stain, culture, and sensitivity to clarify diagnosis, particularly in more severe or refractory cases

-   Moderate to severe eye pain, photophobia, or change in visual acuity should raise suspicion for more serious causes.

Treatment
---------

-   Uncomplicated cases can be treated with a topical antibiotic such as tobramycin, trimethoprim/polymyxin B, a fluoroquinolone or chloramphenicol four times daily for 5--7 days to accelerate recovery

-   Patients should be seen every 2--3 days until signs and symptoms are resolved

-   Failure to respond to topical antibiotics may warrant referral to a specialist.

Indications for specialist referral
-----------------------------------

-   Change in visual acuity

-   Evidence of keratitis and/or anterior uveitis on slit-lamp examination

-   Moderate-to-severe eye pain

-   Failure to improve or worsening of symptoms in spite of treatment.
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###### 

Randomized controlled trials comparing antibiotics with placebo

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                       Number of patients randomized   Interventions                          Outcome measures                                Results
  -------------------------------------------- ------------------------------- -------------------------------------- ----------------------------------------------- --------------------------------------------------------------------------------------------------
  Abelson et al[@b4-opth-4-1451]               279                             One group received azithromycin\       Clinical resolution and bacterial eradication   Higher rate of microbial and clinical cure with antibiotic.
                                                                               One group received "vehicle"                                                           

  Everitt et al[@b5-opth-4-1451]               307                             Two groups received chloramphenicol\   Symptomatic relief                              Antibiotic decreased the duration of symptoms.
                                                                               One group received placebo                                                             

  Hwang et al[@b6-opth-4-1451]                 249                             One group received levofloxacin\       Clinical resolution and bacterial eradication   Higher rate of microbial and clinical cure with antibiotic.
                                                                               One group received placebo                                                             

  Karpecki et al[@b7-opth-4-1451]              269                             One group received besifloxacin\       Clinical resolution and bacterial eradication   Higher rate of microbial and clinical cure with antibiotic
                                                                               One group received "vehicle"                                                           

  Leibowitz[@b8-opth-4-1451]                   177                             One group received ciprofloxacin\      Culture results                                 Higher rate of microbial cure with antibiotic.
                                                                               One group received placebo                                                             

  Lichtenstein and Rinehart[@b9-opth-4-1451]   167                             One group received levofloxacin\       Clinical resolution and bacterial eradication   Higher rate of microbial and clinical cure with antibiotics.
                                                                               One group received ofloxacin\                                                          
                                                                               One group received placebo                                                             

  Miller et al[@b10-opth-4-1451]               284                             One group received norfloxacin\        Bacterial eradication and clinical resolution   Higher rate of microbial and clinical cure with antibiotic.
                                                                               One group received placebo                                                             

  Rietveld et al[@b11-opth-4-1451]             181                             One group received fusidic acid\       Clinical resolution and bacterial eradication   No difference in clinical recovery rate but higher rate of microbial eradication with antibiotic
                                                                               One group received placebo                                                             

  Rose et al[@b12-opth-4-1451]                 326                             One group received chloramphenicol\    Clinical cure by day 7                          No significant difference between antibiotic and placebo
                                                                               One group received placebo                                                             

  Tepedino et al[@b13-opth-4-1451]             957                             One group received besifloxacin\       Clinical resolution and bacterial eradication   Higher rate of microbial and clinical cure with antibiotic
                                                                               One group received "vehicle"                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Topical antibiotics used to treat bacterial conjunctivitis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotic                        Class                                      Coverage                  Mechanism        Availability
  --------------------------------- ------------------------------------------ ------------------------- ---------------- -----------------------------------------------------------
  Azithromycin                      Macrolide                                  Broad-spectrum            Baceriostatic    Azasite^®^ 1% (Inspire Pharmaceuticals Inc)

  Besifloxacin                      Fluoroquinolone                            Broad-spectrum            Bactericidal     Besivance^®^ 0.6% (Bausch and Lomb)

  Chloramphenicol                   Chloramphenicol                            Broad-spectrum            Bacteriostatic   Topical drops not marketed in US\
                                                                                                                          Optrex Infected Eyes^®^ 0.5% in UK

  Ciprofloxacin                     Fluoroquinolone                            Broad-spectrum            Bactericidal     Ciloxan^®^ 0.3% (Alcon Laboratories Inc)\
                                                                                                                          Ointment or drops

  Fusidic acid                      Protein synthesis inhibitor                Primarily Gram-positive   Bacteriostatic   Not available in US\
                                                                                                                          Fucithalmic^®^ 1% (Leo Pharma) in Canada and UK

  Gatifloxacin                      Fluoroquinolone                            Broad-spectrum            Bactericidal     Zymar 0.3% (Allergan Inc)

  Gentamicin                        Aminoglycoside                             Primarily Gram-negative   Bactericidal     Generic 0.3% drops

  Levofloxacin                      Fluoroquinolone                            Broad-spectrum            Bactericidal     Iquix^®^ 1.5% (Vistakon Pharmaceuticals)

  Lomefloxacin                      Fluoroquinolone                            Broad-spectrum            Bactericidal     Not available in US

  Moxifloxacin                      Fluoroquinolone                            Broad-spectrum            Bactericidal     Vigamox^®^ 0.5% (Alcon Laboratories Inc)

  Neomycin-polymyxin B-gramicidin   Aminoglycoside, polymyxin and gramicidin   Broad-spectrum            Bactericidal     Neosporin^®^ (King Pharmaceuticals Inc)

  Netilmicin                        Aminoglycoside                             Primarily Gram-negative   Bactericidal     Not available in US

  Norfloxacin                       Fluoroquinolone                            Broad-spectrum            Bactericidal     Chibroxin 0.3% (Merck and Co Inc)\
                                                                                                                          Not available in US

  Ofloxacin                         Fluoroquinolone                            Broad-spectrum            Bactericidal     Generic 0.3% eye drops

  Providone-iodine                                                             Broad-spectrum            Bactericidal     Betadine 5% (Alcon Laboratories Inc)

  Rifamycin                         Rifamycin                                  Broad-spectrum            Bactericidal     Not available in US

  Tobramycin                        Aminoglycoside                             Primarily Gram-negative   Bactericidal     Tobrex^®^ 0.3% (Alcon Laboratories Inc) ointment or drops
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Randomized controlled trials comparing different topical antibiotics

  Author                                   Number of randomized patients                  Interventions                                                       Outcome measures                                                                                Results
  ---------------------------------------- ---------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Adenis at al[@b14-opth-4-1451]           131                                            0.3% ciprofloxacin versus 0.3% norfloxacin                          Clinical resolution and bacterial eradication                                                   No difference between the two antibiotics
  Adenis et al[@b15-opth-4-1451]           41                                             0.3% ciprofloxacin versus 1% rifamycin                              Clinical resolution and bacterial eradication                                                   Higher clinical cure rate with ciprofloxacin on day 7 (but below statistical significance: *P* = 0.061), no difference in microbial cure
  Bloom et al[@b16-opth-4-1451]            464                                            Ciprofloxacin versus tobramycin                                     Clinical resolution and bacterial eradication                                                   No difference between the two antibiotics
  Bremond-Gignac et al[@b17-opth-4-1451]   150                                            1.5% azithromycin versus 0.3% tobramycin                            Clinical resolution and bacterial eradication                                                   Greater bacteriologic cure with azithromycin on day 3, no difference in clinical or bacteriologic cure on day 9
  Chisari et al[@b18-opth-4-1451]          190                                            Ciprofloxacin versus norfloxacin                                    Clinical resolution and bacterial eradication                                                   No difference between the two antibiotics
  Cochereau et al[@b19-opth-4-1451]        1043                                           1.5% azithromycin for 3 days versus 0.3% tobramycin for 7 days      Clinical resolution and bacterial eradication                                                   Higher rate of clinical cure with azithromycin on day 3, no difference in clinical or bacteriologic cure on day 9
  Denis et al[@b20-opth-4-1451]            1043                                           1.5% azithromycin for 3 days versus 0.3% tobramycin for 7 days      Microbiological resolution                                                                      No difference between the two groups
  Gallenga et al[@b21-opth-4-1451]         99                                             0.3% lomefloxacin BID versus 0.3% tobramycin QID                    Clinical resolution and bacterial eradication                                                   No difference between the two groups
  Granet et al[@b22-opth-4-1451]           84 eyes of 56 patients                         Polymyxin/trimethoprim QID versus 0.5% moxifloxacin TID             Relief of signs and symptoms                                                                    Faster clinical resolution with moxifloxacin
  Gwon[@b23-opth-4-1451]                   345                                            0.3% ofloxacin versus 0.3% tobramycin                               Clinical resolution and bacterial eradication                                                   Similar efficacy between the two treatments, more rapid symptom relief with ofloxacin
  Isenberg et al[@b24-opth-4-1451]         459 total, 124 culture-positive for bacteria   1.25% povidoneiodine versus neomycin-polymyxin B-gramicidin         Clinical resolution                                                                             No difference between povidoneiodine and antibiotic
  Jackson et al[@b25-opth-4-1451]          484                                            1% fusidic acid versus 0.3% tobramycin                              Clinical resolution, bacterial eradication, compliance, subjective "convenience" of treatment   No difference between clinical or microbial resolution, higher compliance and convenience with fusidic acid among younger patients
  Kernt et al[@b26-opth-4-1451]            276                                            Enhanced-viscosity 0.3% tobramycin BID versus 0.3% tobramycin QID   Clinical resolution                                                                             No difference between the two groups
  Lichtenstein et al[@b11-opth-4-1451]     167                                            0.5% levofloxacin versus 0.3% ofloxacin (versus placebo)            Clinical resolution and bacterial eradication                                                   Higher microbial eradication rate with levofloxacin in 2--11-year-old children; no difference between the two antibiotics in other age groups
  Malminiemi et al[@b27-opth-4-1451]       45                                             0.3% lomefloxacin versus 1% fusidic acid                            Clinical resolution and bacterial eradication                                                   No difference in clinical recovery but higher rate of bacterial eradication with lomefloxacin after 3--5 days
  McDonald et al[@b28-opth-4-1451]         1161                                           0.6% besifloxacin versus 0.3% moxifloxacin                          Clinical resolution and bacterial eradication                                                   No difference between the two groups; higher rate of eye irritation with moxifloxacin
  Milazzo et al[@b29-opth-4-1451]          45                                             0.3% netilmicin versus 0.3% tobramycin                              Clinical resolution and bacterial eradication                                                   No difference in clinical resolution, better microbiologic outcome with netilmicin
  Miller et al[@b30-opth-4-1451]           246                                            Norfloxacin versus chloramphenicol                                  Clinical resolution and bacterial eradication                                                   No difference between the two groups
  Normann et al[@b31-opth-4-1451]          456 newborns                                   1% fusidic acid versus 0.5% chloramphenicol                         Clinical resolution and compliance                                                              No difference in efficacy but better compliance with fusidic acid
  Papa et al[@b32-opth-4-1451]             209                                            Netilmicin versus gentamicin                                        Clinical resolution and bacterial eradication                                                   Greater efficacy rate with netilmicin
  Power et al[@b33-opth-4-1451]            ?                                              0.3% ciprofloxacin versus 0.5% chloramphenicol                      Clinical resolution and bacterial eradication                                                   No difference between the two groups
  Protzko et al[@b34-opth-4-1451]          743                                            1% azithromycin in DuraSite versus 0.3% tobramycin                  Safety, clinical resolution and bacterial eradication                                           Similar safety and efficacy between the two groups
  Robert et al[@b35-opth-4-1451]           1043                                           1.5% azithromycin versus 0.3% tobramycin                            Clinical resolution                                                                             No difference between the two groups
  Schwab et al[@b36-opth-4-1451]           423                                            0.5% levofloxacin versus 0.3% ofloxacin                             Clinical resolution and bacterial eradication                                                   More rapid microbial resolution with levofloxacin, similar clinical resolution
  Tabbara et al[@b37-opth-4-1451]          40                                             0.3% lomefloxacin versus 0.3% ofloxacin                             Clinical resolution                                                                             No difference between the two groups
  Zhang et al[@b38-opth-4-1451]            132                                            0.3% levofloxacin versus 0.3% ofloxacin                             Clinical resolution and bacterial eradication                                                   No difference between the two groups

**Abbreviations:** BID, twice daily; TID, three times daily; QID, four times daily.

###### 

Randomized controlled trials comparing different regimens of treatment

  Author                            Number of randomized patients   Interventions                                                                                Outcome measures                                        Results
  --------------------------------- ------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------- --------------------------------------
  Friedlaender[@b39-opth-4-1451]    50                              0.3% ofloxacin BID versus QID                                                                Clinical resolution and bacterial eradication           No difference between the two groups
  Szaflik et al[@b40-opth-4-1451]   120                             0.5% levofloxacin TID × 5 days versus "standard regimen" (Q2H × 2 days, then Q4H × 3 days)   Clinical resolution and bacterial eradication           No difference between the two groups
  Wald et al[@b41-opth-4-1451]      80                              Oral cefixime + topical placebo versus topical polymyxinbacitracin + oral placebo            Clinical resolution and bacterial eradication           No difference between the two groups
  Yee et al[@b42-opth-4-1451]       104                             0.3% gatifloxacin BID versus QID                                                             Clinical resolution, bacterial eradication and safety   No difference between the two groups

**Abbreviations:** Q2H, two hourly; Q4H, four hourly; BID, twice daily; TID, three times daily; QID, four times daily.
